Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer

被引:9
作者
Ishibiki, Y [1 ]
Kitajima, M [1 ]
Sakamoto, K [1 ]
Tomiki, Y [1 ]
Sakamoto, S [1 ]
Kamano, T [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Surg 1, Bunkyo Ku, Tokyo 1138421, Japan
关键词
5-fluorourach; thymidylate synthase; dihydropyrimidine; dehydrogenase; colorectal cancer;
D O I
10.1177/147323000303100303
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
To identify factors that influence the clinical response to 5-fluorouracil (5-FU), we studied the correlation between in vitro sensitivity to 5-FU and the expression of seven biological markers. The markers, thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), pyrimidine nucleoside phosphorylase, p53 (wild/mutant), p21, cyclo-oxygenase-2, and inducible nitric oxide synthase were measured in tumour tissues from 32 colorectal. cancer patients. The activities of TS and DPD were significantly lower in the tumours sensitive to 5-FU compared with those that were not sensitive to 5-FU. In tumours with TS < 3.7 pmol/min per mg protein and DPD < 98 pmol/min per mg protein, the percentage of cases sensitive to 5-FU (67%) and the mean percentage inhibition of tumour cells by S-FU (42.8%) were significantly higher than in the other tumours (0% and 13.1%, respectively). The other biological markers did not correlate with in vitro sensitivity to 5-FU. Tumour sensitivity to S-FU can be more precisely predicted by taking the activities of both TS and DPD into consideration than by using either alone.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 14 条
[1]   Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil [J].
Aschele, C ;
Debernardis, D ;
Bandelloni, R ;
Cascinu, S ;
Catalano, V ;
Giordani, P ;
Barni, S ;
Turci, D ;
Drudi, G ;
Lonardi, S ;
Gallo, L ;
Maley, F ;
Monfardini, S .
ANNALS OF ONCOLOGY, 2002, 13 (12) :1882-1892
[2]  
Banerjee D, 2000, CANCER RES, V60, P2365
[3]   A ROLE FOR DIHYDROPYRIMIDINE DEHYDROGENASE AND THYMIDYLATE SYNTHASE IN TUMOR SENSITIVITY TO FLUOROURACIL [J].
BECK, A ;
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
RENEE, N ;
MILANO, G .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) :1517-1522
[4]   FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J].
DIASIO, RB ;
BEAVERS, TL ;
CARPENTER, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :47-51
[5]   CYTOKINES INDUCE THYMIDINE PHOSPHORYLASE EXPRESSION IN TUMOR-CELLS AND MAKE THEM MORE SUSCEPTIBLE TO 5'-DEOXY-5-FLUOROURIDINE [J].
EDA, H ;
FUJIMOTO, K ;
WATANABE, S ;
URA, M ;
HINO, A ;
TANAKA, Y ;
WADA, K ;
ISHITSUKA, H .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (05) :333-338
[6]   RESPONSE TO FLUOROURACIL THERAPY IN CANCER-PATIENTS - THE ROLE OF TUMORAL DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY [J].
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
DASSONVILLE, O ;
RENEE, N ;
SCHNEIDER, M ;
THYSS, A ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1663-1670
[7]  
HARAGUCHI M, 1993, CANCER RES, V53, P5680
[8]   Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil [J].
Ishikawa, Y ;
Kubota, T ;
Otani, Y ;
Watanabe, M ;
Teramoto, T ;
Kumai, K ;
Takechi, T ;
Okabe, H ;
Fukushima, M ;
Kitajima, M .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (01) :105-112
[9]  
JOHNSTON PG, 1995, CANCER RES, V55, P1407
[10]  
Kobayashi H, 1997, INT J ONCOL, V11, P449